Navigation Links
Genzyme Announces Presentation of New Positive Data on Carticel(R)

Large Outcome Studies Reported at AAOS Annual Meeting Support Longterm

Clinical Duration

CAMBRIDGE, Mass., March 10 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ), today announced findings from a large, multicenter, observational study that investigated the long-term durability of Carticel(R) (autologous cultured chondrocytes) in patients who had pain and functional impairment from defects in the articular cartilage of their knee. These findings revealed that almost 90 percent of patients treated with Carticel who experienced improvement in knee function at an early follow-up, sustained their improvement for up to almost 10 years. The data were presented at this week's American Academy of Orthopaedic Surgeons' (AAOS) annual meeting in San Fransisco.

"We knew that autologous chondrocyte implantation (ACI) worked for select patients, but did it last?" said Allen Anderson, MD, (Nashville, TN) a leading orthopaedic surgeon in the field of sports medicine who presented the data at the medical meeting. "These data suggest that the ACI technique not only works, but when it works, the results will last for a long time. Similar results of long term durability had been previously reported by Lars Peterson, M.D., but this multicenter experience suggests that sustainable results can be reproduced by others."

Study Results

The objectives of the study were to determine if a patient's improvement assessed at an early timepoint, defined as 1 to 5 years (mean 4.6 years) after Carticel implantation, could be sustained at a much later time point defined as 6 to 10 years (mean 9.2 years).

Seventy-two patients were enrolled from 35 different centers across the US. All patients enrolled had low functional scores (overall condition score of 3.4 points on the Modified Cincinnati Knee Rating System). Patients were young (mean age of 37 years) and had moderate to large lesions (mean lesion size of 4.3 cm2) on the femoral chondyles (Lateral Femoral Chondyle, Medial Femoral Chondyle and Trochlea) and most patients had undergone at least one previous treatment for their cartilage injury. At their early follow-up, 75 percent of all patients experienced significant improvement in their knee function (mean improvement of 4.3 in overall condition). Of those patients, 87 percent sustained improvement at the later follow-up time point.

"Long-term durability of Carticel had not been evaluated in the United States and there was a critical need to determine if Carticel patients experienced sustained improvement," said Leanna M. Caron, vice president and general manager of Genzyme Biosurgery, the division that manufactures and commercializes Carticel. "This study demonstrates both the durability and value of Carticel and leads the field to conclude that a vast majority of this patient population maintained improvement years following their initial procedure."

Also at the AAOS meeting, a separate study conducted at the Brigham and Women's Hospital in Boston, Mass., Dr. Tom Minas reported the findings of a study that compared the results of ACI following a marrow stimulation technique versus no significant treatment (including simple debridement) performed on the same cartilage defect. The results indicate that marrow stimulation techniques may compromise the successful outcome of future ACI. Investigators collected data from 329 consecutive patients treated with Carticel for large and multiple defects (4.8 cm2 per lesion and 8.7 cm2 per patient) and had at least two years follow-up. They concluded that patients who had a previous marrow stimulation technique and were subsequently treated with ACI were three times more likely to fail than patients who had not undergone a marrow stimulation technique prior to treatment with ACI.

"The data show that in this patient population marrow stimulation techniques like microfracture are not benign and can compromise a patient's ability to benefit from a subsequent treatment with ACI, effectively limiting their future treatment options," said Tom Minas, MD, an internationally renowned orthopaedic surgeon for his extensive work in the field of Cartilage Repair and principal investigator in this study. "Orthopaedic surgeons should reconsider using marrow stimulation techniques as first-line treatment for patients with larger chondral lesions. These techniques should be reserved for patients with smaller defects, in younger patients, where a good result is more predictable."

A Unique Cell Therapy

More than 14,000 patients in the United States have had Carticel implants. Carticel is used by orthopaedic surgeons to treat patients who have clinically significant articular cartilage lesions on the thigh bone part of the knee caused by acute or repetitive trauma that have not responded to a prior cartilage repair procedure. Carticel should only be used in conjunction with debridement, placement of a periosteal flap and rehabilitation. The independent contributions of the autologous cultured chondrocytes and other components of the therapy to outcome are unknown. Carticel employs a unique process to grow a patient's own cartilage cells for implantation to correct certain types of damage. The treatment starts when an orthopaedic surgeon trained in the use of Carticel provides Genzyme with a biopsy of healthy cartilage taken from a patient's knee in an arthroscopic procedure. Technicians at Genzyme's cell culture laboratory in Cambridge, MA, use proprietary methods to grow millions of cells from this biopsy. The cells are then delivered to the hospital, where the surgeon implants them into the patient's knee defect in a surgical procedure.

Carticel was the first cell therapy to be approved by the FDA. First introduced in March of 1995, Carticel received accelerated approval from the FDA in August of 1997 after the FDA instituted specific cell therapy guidelines. Under accelerated approval, the FDA required Genzyme to conduct confirmatory post-marketing clinical studies. Genzyme successfully completed the confirmatory studies and, in June of 2007, the FDA deemed the commitment satisfied.

To learn more about Carticel please visit

Cell Therapy Expertise at Genzyme

Genzyme has more than a decade of experience in developing and manufacturing autologous cell therapy products that have been used to treat thousands of patients. Epicel(R) (cultured epidermal autografts), a cell therapy for treating patients with severe burns, is also manufactured by Genzyme. Together, Carticel and Epicel represent the first such products ever brought to market in the United States, providing Genzyme with superior scientific and commercial expertise in this field.

About Carticel

CARTICEL is for autologous use and is indicated for the repair of symptomatic cartilage defects of the femoral condyle (medial, lateral or trochlea), caused by acute or repetitive trauma, in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure (e.g., debridement, microfracture, drilling/abrasion arthroplasty, or osteochondral allograft/autograft). CARTICEL should only be used in conjunction with debridement, placement of a periosteal flap and rehabilitation. The independent contributions of the autologous cultured chondrocytes and other components of the therapy to outcome are unknown. It is not indicated for the treatment of cartilage damage associated with generalized osteoarthritis. It is not recommended for patients whose knee meniscus has been surgically removed unless the patient has undergone surgical reconstruction prior to or concurrent with CARTICEL implantation.

Pre-existing conditions including meniscal tears, joint instability or malalignment of the joint should be corrected prior to or concurrent with CARTICEL implantation. It should not be used in patients with a known history of hypersensitivity to gentamicin, other aminoglycosides or materials of bovine origin. CARTICEL is not routinely tested for transmissible infectious diseases and may transmit disease to the healthcare provider handling CARTICEL. In addition, it should not be used in patients who have previously had cancer in the bones, cartilage, fat or muscle of the treated limb. Use in children, patients over age 65, or in joints other than the knee has not yet been assessed.

The occurrence of subsequent surgical procedures (SSPs), primarily after arthroscopy, following CARTICEL implantation is common. In the Study of the Treatment of Articular Repair (STAR), forty-nine percent (49%) of patients underwent an SSP on the treated knee, irrespective of their relationship to CARTICEL, during the 4-year follow-up. The most common serious adverse events (greater than or equal to 5% of patients), derived from STAR, include arthrofibrosis/joint adhesions, graft overgrowth, chondromalacia or chondrosis, cartilage injury, graft complication, meniscal lesion, graft delamination, and osteoarthritis. For more information about Carticel, visit

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 9,500 employees in locations spanning the globe and 2006 revenues of $3.2 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation. In 2006 and 2007, Genzyme was selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

GENZYME(R) and SYNVISC(R) are registered trademarks of Genzyme Corporation SYNVISC ONE(TM) and SYNVISC-ONE(TM) are trademarks of Genzyme Corporation

Genzyme's press releases and other company information are available at and by calling Genzyme's investor information line at 1-800- 905-4369 within the United States or 1-678-999-4572 outside the United States.

Media Contact: Investor Contact:

Sarah Millerick Catie Forte

(617) 768-6438 (617) 768-6881

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
2. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
3. Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
4. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
(Date:11/30/2015)... MOUNTLAKE TERRACE, Wash. and ST. ... Cross and Express Scripts (NASDAQ: ESRX ) today ... benefit agreement. The partnership, which began in 1999, will ... --> --> After evaluating pharmacy ... process, Premera concluded that Express Scripts continues to offer ...
(Date:11/30/2015)... CHICAGO , Nov. 30, 2015   Nuance ... The National Decision Support Company (NDSC) today ... support and collaboration capabilities that utilize the American College ... and healthcare provider organizations to comply with current ... --> --> By combining clinical ...
(Date:11/30/2015)... , Nov. 30, 2015 Varian Medical Systems (NYSE: ... an educational partnership with Apollo Hospitals Group, the largest hospital chain ... will help train radiation technologists in the country. The MoU was ... Apollo Knowledge, and Ashok Kakkar , Varian,s India ... India , Varian intends to deploy its ...
Breaking Medicine Technology:
(Date:11/30/2015)... , ... November 30, 2015 , ... At Grand Dental ... and convenient setting. , When you have dental problems, you need to turn to ... can effectively diagnose and treat your needs, a friendly dentist who counsels you on ...
(Date:11/30/2015)... ... November 30, 2015 , ... Using a combination of two blood ... children and adults, according to a new study by researchers at the School of ... Children and Adults: Using Combinations of Blood Glucose Tests ,” published in Frontiers in ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... in general dentistry out of Glen Ridge, NJ. He has both advanced ... achieve optimal mastication. He is also an expert in cosmetic dentistry. He ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... a new study by UPMC and KingMed Diagnostics researchers. ... three years found that consultation with UPMC pathologists resulted in significantly altered treatment ...
(Date:11/30/2015)... ... November 30, 2015 , ... ”Dying Words: The AIDS Reporting of ... December 1, 2015, to coincide with World AIDS Day. The multi-media project will be ... the AIDS epidemic as he was dying of the disease. , A collaborative effort ...
Breaking Medicine News(10 mins):